18:3026 mars
NEWBRY
Kallelse till extra bolagsstämma i Newbury Pharmaceuticals AB
Notice of Extraordinary General Meeting of Newbury Pharmaceuticals AB
Bolag
Newbury Pharmaceuticals
NEWBRYFirst North StockholmHälsovårdLäkemedel & Handel
Newbury Pharmaceuticals är verksamt inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget bedriver sin verksamhet inom den skandinaviska marknaden. Newbury Pharmaceuticals grundades år 2020 och har sitt huvudkontor i Lund.
Senaste nyheter och pressmeddelanden
Bolagets senaste flöde, utan extra fluff.
13:0026 mars
NEWBRY
Newbury Pharmaceuticals extends and increases loan agreement to SEK 30m, convenes EGM
Newbury Pharmaceuticals AB has agreed to extend and increase the existing loan agreement with AB Slädens Pensionsstiftelse nr 3, securing SEK 30 million in total financing through to 30 June 2027, and will convene an Extraordinary General Meeting to seek shareholder approval of the amendment.
15:4518 mars
NEWBRY
Newbury Pharmaceuticals has entered into a new partnership for Prucalopride tablets
Newbury has signed a contract with a new partner to register and launch Prucalopride in Sweden. Prucalopride, 1 and 2 mg tablets, is a selective, high affinity 5-HT4 receptor agonist which targets the impaired motility associated with chronic constipation, thus normalizing bowel movements.
11:0029 jan.
NEWBRY
Newbury Pharmaceuticals Secures 12-Month Pazopanib Tender in Denmark
Newbury Pharmaceuticals is pleased to announce that it has been awarded a 12-month tender for Pazopanib Newbury with the Danish procurement body Amgros, commencing on June 1, 2026.
07:0021 jan.
NEWBRYinterim
Newbury Pharmaceuticals interim report September 2025 – November 2025
10:1514 jan.
NEWBRY
ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB
The annual general meeting of Newbury Pharmaceuticals was held on Wednesday, 14 January 2026. At the meeting 10 977 485 shares were represented, which corresponds to approx. 36 percent of the total number of shares. The summary below shows the resolutions adopted at the AGM. The resolutions were adopted unanimously.
19:3010 dec.
NEWBRYannual
Newbury Pharmaceuticals publishes its annual report for 2024/2025
Newbury Pharmaceuticals AB has published its annual report for the 2024/2025 financial year.
15:1509 dec.
NEWBRY
Kallelse till årsstämma i Newbury Pharmaceuticals AB
Notice of annual general meeting